arrow
D

Dario Romagnoli

Hospital of Prato
H指数:13
被引数:922

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer

通过体细胞拷贝数异常实现乳腺癌中ctDNA的敏感与精确检测

2025-03-080
OA
Sensitive tumor detection, accurate quantification, and ER subtyping using low-pass methylome of liquid biopsy samples from patients (pts) with metastatic breast cancer (mBC)
2024-05-020
PRE
RBsig geneexpression signature in patients with endocrine resistant metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial
2024-05-020
PRE
Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches
2024-05-020
PRE
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

BRCA2种系突变鉴定对PARP抑制剂有反应的胃癌

2023-05-026
OAAI
Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures in patients with advanced breast cancer treated with palbociclib in combination with endocrine therapy in the PALOMA-2 and 3 trials
2023-03-010
PRE
Circulating tumor cells, immunohistochemical subtypes, and genes mutation as prognostic markers in HER2 negative metastatic breast cancer patients candidates to chemotherapy
2023-03-010
PRE
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
2021-06-2899
OAAI
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

ER阳性,HER2-negative晚期乳腺癌患者的循环肿瘤细胞和palbociclib治疗: TREnd试验的转化子研究结果

2021-03-2418
OAAI
Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR plus ) operable breast cancer (BC)
2020-02-150
PRE
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
2019-12-114
OAAI